Qiagen N.V. (NYSE:QGEN) Stock Has Consensus Target Price of $43.93 According to Brokerages

Key Points

• Analyst consensus is “Hold”: Nine of 14 covering firms rate Qiagen shares Hold, while four recommend Buy and one Strong Buy. The average 12-month price target is $43.93, below the stock’s reported $48.87 opening price.
• Qiagen exceeded quarterly expectations: The company reported earnings of $0.62 per share versus the $0.60 consensus estimate, while revenue reached $535.04 million, above expectations of $527.50 million.
• Institutional ownership remains substantial: Hedge funds and other institutional investors own about 70% of Qiagen’s stock, with several firms recently adding or initiating positions.

Shares of Qiagen N.V. (NYSE:QGEN - Get Free Report) have been assigned an average rating of "Hold" from the fourteen research firms that are presently covering the stock, Marketbeat.com reports. Nine investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $43.93.

A number of research firms have recently issued reports on QGEN. UBS Group started coverage on Qiagen in a research report on Wednesday, September 9th. They set a "neutral" rating and a $47.00 price target on the stock. Barclays set a $40.00 price objective on Qiagen and gave the company an "equal weight" rating in a report on Friday, August 7th. TD Cowen restated a "hold" rating on shares of Qiagen in a report on Wednesday, July 15th. Citigroup reaffirmed a "neutral" rating and issued a $45.00 price objective (up from $38.00) on shares of Qiagen in a research note on Monday, August 10th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Qiagen from $50.00 to $55.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 14th.

Qiagen Stock Up 5.0%

Shares of NYSE:QGEN opened at $48.87 on Wednesday. Qiagen has a 52-week low of $32.53 and a 52-week high of $57.81. The stock has a market cap of $10.07 billion, a P/E ratio of 25.04, a price-to-earnings-growth ratio of 4.63 and a beta of 0.61. The business's 50 day moving average is $44.01 and its 200 day moving average is $40.45. The company has a quick ratio of 2.31, a current ratio of 2.85 and a debt-to-equity ratio of 0.48.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.60 by $0.02. The company had revenue of $535.04 million for the quarter, compared to the consensus estimate of $527.50 million. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. Qiagen's quarterly revenue was up .2% on a year-over-year basis. During the same period last year, the business posted $0.60 EPS. Qiagen has set its FY 2026 guidance at 2.430- EPS. Sell-side analysts predict that Qiagen will post 2.43 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Engineers Gate Manager LP boosted its position in Qiagen by 107.7% during the 2nd quarter. Engineers Gate Manager LP now owns 74,567 shares of the company's stock valued at $2,916,000 after acquiring an additional 38,658 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in shares of Qiagen in the 1st quarter valued at $2,518,000. Baader Bank Aktiengesellschaft purchased a new position in shares of Qiagen in the 1st quarter valued at $1,368,000. Public Employees Retirement System of Ohio purchased a new position in shares of Qiagen in the 2nd quarter valued at $2,836,000. Finally, WINTON GROUP Ltd bought a new position in shares of Qiagen in the 2nd quarter worth $1,423,000. Hedge funds and other institutional investors own 70.00% of the company's stock.

About Qiagen

QIAGEN N.V. NYSE: QGEN is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.